Patent intelligence · US
US 9587008
Method of producing recombinant vitamin K dependent proteins
Method of producing recombinant vitamin K dependent proteins
Patent details — US 9587008
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 7, 2017
- Expiration
- Mar 2, 2037
- Applicant
- APTEVO BIOTHERAPEUTICS LLC
- Claims
- 14
- CPC classes
- A61K, A61K38/36, A61P, A61P7/04
Quick answer
US 9587008 (Method of producing recombinant vitamin K dependent proteins) is held by APTEVO BIOTHERAPEUTICS LLC. Status: granted. Granted Mar 7, 2017. Expires Mar 2, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APTEVO BIOTHERAPEUTICS LLC
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/36, A61P, A61P7/04
More from APTEVO BIOTHERAPEUTICS LLC
Related pharmaceutical patents in our USPTO index.
-
US 11939392
CD123 binding proteins and related compositions and methods
granted -
US 11725060
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
granted -
US 11352426
CD3 binding polypeptides
granted -
US 11312786
Oncofetal antigen binding proteins and related compositions and methods
granted -
US 11242400
CD123 binding proteins and related compositions and methods
granted -
US 10676533
Methods of treatment of CD123 overexpressing disorders
granted -
US 10307481
CD37 immunotherapeutics and uses thereof
granted -
US 10239949
Oncofetal antigen binding proteins and related compositions and methods
granted
Frequently asked questions
What is US patent 9587008?
US 9587008 (Method of producing recombinant vitamin K dependent proteins) is held by APTEVO BIOTHERAPEUTICS LLC. Status: granted. Granted Mar 7, 2017. Expires Mar 2, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9587008?
APTEVO BIOTHERAPEUTICS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 9587008 expire?
Our index shows an expiration date of Mar 2, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.